Initial Statement of Beneficial Ownership (3)
February 13 2023 - 06:56PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Birchview
Capital, LP |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
12/5/2021
|
3. Issuer Name and Ticker or Trading
Symbol AZIYO BIOLOGICS, INC. [AZYO] |
(Last)
(First)
(Middle)
688 PINE STREET, SUITE D |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director ___X___
10% Owner
_____ Officer (give title
below) _____
Other (specify below)
|
(Street)
BURLINGTON, VT 05401
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Class A Common Stock |
1417923 |
I |
See footnotes (1)(2)(3)(4) |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
Matthew Strobeck is the
Managing Member of Birchview Capital GP, LLC, who is the General
Partner of Birchview Capital, LP. Matthew Strobeck is the Managing
Member of Birchview Partners LLC, who is the Manager of Birchview
Fund, LLC ("the Fund"). Birchview Capital, LP is the investment
manager of Birchview Fund, LLC. |
(2) |
Birchview Fund, LLC acquired
1,134,905 of the shares. Matthew Strobeck personally acquired
165,094 of the shares and acquired an additional 117,924 of the
shares in custodial accounts in his name (the "Strobeck
Shares"). |
(3) |
Of the Strobeck Shares, all
283,018 of the Strobeck Shares were held in separately managed
accounts ("SMA") for which Birchview Capital, LP provided
investment advice. |
(4) |
As the investment manager of
the Fund, Birchview Capital, LP possesses the power to vote and
dispose or direct the disposition of all the 1,134,905 shares held
by the Fund. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Birchview Capital, LP
688 PINE STREET, SUITE D
BURLINGTON, VT 05401 |
|
X |
|
|
Birchview Fund LLC
688 PINE STREET, SUITE D
BURLINGTON, VT 05401 |
|
X |
|
|
Strobeck Matthew
688 PINE STREET, SUITE D
BURLINGTON, VT 05401 |
|
X |
|
|
Signatures
|
Birchview Capital, LP By: /s/ Matthew Strobeck
Matthew Strobeck, Managing Member of Birchview Capital GP, LLC,
General Partner of Birchview Capital, LP |
|
2/13/2023 |
**Signature
of Reporting Person |
Date |
Birchview Fund LLC By: /s/ Matthew Strobeck
Matthew Strobeck, Managing Member of Birchview Partners LLC,
Manager of Birchview Fund LLC |
|
2/13/2023 |
**Signature
of Reporting Person |
Date |
/s/ Matthew Strobeck Matthew
Strobeck |
|
2/13/2023 |
**Signature
of Reporting Person |
Date |
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
* |
If the form is filed by more than one
reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From May 2023 to Jun 2023
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Jun 2022 to Jun 2023